ESR1 and breast carcinoma: Another possibility is that treatments with synthetic ligands, particularly at higher concentrations, may activate negative feedback mechanisms which then lead to the inactivation or degradation of LXR, reminiscent of high doses of estrogens used to block estrogen receptor functions in the early days of endocrine treatment of breast cancer [31], [32].